SCHEMBL6722283

SCHEMBL6722283

CC(=O)OC(CC(C)(C)O)c1nc2cnc3ccccc3c2[nH]1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DUSP10 Q9Y6W6 1/20 0.34
TLR7 Q9NYK1 5/20 0.33
HPGD P15428 1/20 0.32
GABRA1 P14867 7/20 0.31
GABRG2 P18507 7/20 0.31
GABRB3 P28472 7/20 0.31
GABRA5 P31644 7/20 0.31
GABRA3 P34903 7/20 0.31
GABRA2 P47869 7/20 0.31
GABRA6 Q16445 4/20 0.31
GABRP O00591 3/20 0.31
GABRD O14764 3/20 0.31
GABRB1 P18505 3/20 0.31
GABRB2 P47870 3/20 0.31
GABRA4 P48169 3/20 0.31
GABRE P78334 3/20 0.31
GABRG1 Q8N1C3 3/20 0.31
GABRG3 Q99928 3/20 0.31
GABRQ Q9UN88 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7219790 0.86 TAAR1 (0.36)
SCHEMBL6723888 0.85 CYP1A2 (0.37)
SCHEMBL6734722 0.83 ALDH1A1 (0.43) HPGD
SCHEMBL6719057 0.81 ADORA3 (0.36) HPGD
SCHEMBL6723519 0.74 NPC1 (0.39)
SCHEMBL8573439 0.74 TAAR1 (0.39)
SCHEMBL7226167 0.72 AAK1 (0.38) DUSP10
SCHEMBL14643309 0.71 MLKL (0.41)
SCHEMBL6724720 0.71 AAK1 (0.37) DUSP10HPGD
SCHEMBL20741624 0.70 G6PD (0.34) DUSP10TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6790961-B2 REACTING A 3-AMINO-4-(SUBSTITUTED)AMINO-2-CHLOROQUINOLINE WITH AN ALKYLCARBONYL CHLORIDE TO FORM THE 2-ALKYLCARBOXAMIDE INTERMEDIATE 3M INNOVATIVE PROPERTIES COMPANY 2004-09-14 US disclosed
US-20040122231-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2004-06-24 US disclosed
US-6686472-B2 Process for preparing 1-substituted, 2-substituted 1-H-imidazo(4,5-c)quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2004-02-03 US disclosed
US-20030212270-A1 Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines 3M INNOVATIVE PROPERTIES COMPANY 2003-11-13 US disclosed
US-6608201-B2 Amidation of a 2-halo-3,4-diaminoquinoline with an acid chloride; dehalogenation, amination with ammonia; cyclization 3M INNOVATIVE PROPERTIES COMPANY 2003-08-19 US disclosed
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2003-06-26 US disclosed
EP-0872478-B1 Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines MINNESOTA MINING & MFG (US) 2002-12-18 EP disclosed
US-6465654-B2 ANTIVIRAL AGENTS, THAT INDUCE BIOSYNTHESIS OF INTERFERON, AND INHIBIT TUMOR FORMATION 3M INNOVATIVE PROPERTIES COMPANY 2002-10-15 US disclosed
US-6348462-B1 VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2002-02-19 US disclosed
US-5977366-A 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY (US) 1999-11-02 US disclosed
EP-0582581-B1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING & MFG (US) 1999-05-06 EP disclosed
EP-0872478-A2 Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-10-21 EP disclosed
US-5605899-A VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-02-25 US disclosed
US-5389640-A Viricides, antitumor agents MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-02-14 US disclosed
WO-1992015582-A1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212270-A1 Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines IFNAR1, IRF3, IFNG DUSP10 2958/4885TLR7 101/4885HPGD 1256/4885
US-20040122231-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines UGT1A4, QARS1, HTR4 DUSP10 4730/4885TLR7 1287/4885HPGD 2185/4885
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines IRF3, IFNAR1, IFNG DUSP10 2719/4885TLR7 105/4885HPGD 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.